MAPT and Alzheimer disease: Plasma p-tau217 was chosen as the main blood-biomarker predictor in the screening model for Aβ positivity for being a robust AD-specific biomarker with a large fold-change in Aβ positive patients with cognitive impairment10, consistently outperforming other p-tau markers in comparison studies12,13,30.